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Type I interferons (IFN-a/h) are potent antiviral cytokines and modulators of the adaptive immune system. They are induced by viral infection
or by double-stranded RNA (dsRNA), a by-product of viral replication, and lead to the production of a broad range of antiviral proteins and
immunoactive cytokines. Viruses, in turn, have evolved multiple strategies to counter the IFN system which would otherwise stop virus growth
early in infection. Here we discuss the current view on the balancing act between virus-induced IFN responses and the viral counterplayers.
D 2005 Elsevier Inc. All rights reserved.
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Viral infections in children and young adults are common
and generally uneventful. In most instances, the patients
recover and either eliminate the virus or incorporate it in a
latent or persistent form without further problems. Although
viruses are obligate intracellular parasites and rely entirely on
the metabolic machinery of the host cell, they usually do not
cause much harm. The main reason is that our body is not
defenseless but makes use of numerous measures to keep
viruses at bay. As we know, the type I interferon system is a
major player in antiviral defense against all kinds of viruses.
Virus-infected cells synthesize and secrete type I interferons
(IFN-a/h) which warn the body of the dangerous intruders.6) 119 – 130
www.e
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to express potent antiviral mechanisms which limit further viral
growth and spread. IFN was discovered almost 50 years ago by
Isaacs and Lindenmann as a cytokine interfering with virus
replication (Isaacs and Lindenmann, 1957). Since then, much
progress has been made in demonstrating how IFNs are
induced and how they work. However, only now we begin to
appreciate to what extent viruses modulate the IFN response
they evoke in the first place. Clearly, viruses would not be
successful pathogens if they had not evolved efficient escape
strategies allowing them to suppress IFN production, to down-
modulate IFN signaling and to block the action of antiviral
effector proteins. It is becoming increasingly clear that the IFN
antagonistic properties determine viral virulence to a great
extent and may contribute to interspecies transmission of so-
called emerging and reemerging viruses. Here, we summarize
recent highlights in our understanding of how cells defend
themselves against viral intruders and how viruses manage to
survive in the face of the powerful IFN system.
The amazing power of the interferon system
The type I IFN system is indispensable for vertebrates to
control viral infections. This is best illustrated in knockout
mice which are unresponsive to IFN-a/h due to targeted
deletions in the type I IFN receptor (Muller et al., 1994). These
mice quickly succumb to viral infections despite having a
normal adaptive immune system (Bouloy et al., 2001; Bray,
2001; Grieder and Vogel, 1999; Hwang et al., 1995; Muller et
al., 1994; Ryman et al., 2000; van den Broek et al., 1995).
Likewise, humans die of viral disease at an early age if they
happen to acquire genetic defects of the IFN system (Dupuis et
al., 2003). The importance of type I IFNs is further
demonstrated in instances where disruption of a single IFN-
effector gene causes a complete loss of innate immunity against
a particular type of virus, leading to overwhelming infection
and rapid death. A telling case is increased susceptibility to
influenza and influenza-like viruses found in inbred mouse
strains due to a defect in the IFN-regulated Mx1 gene
(Lindenmann, 1964; Staeheli et al., 1988). Susceptible animals
are equipped with the full armament of innate and adaptive
immunity with the exception of Mx and resist all sorts of
viruses but not orthomyxoviruses (Haller, 1981; Haller et al.,
1998). Transgenic introduction of mouse or human Mx is
sufficient to turn susceptible mice into resistant animals
(Arnheiter et al., 1990; Pavlovic et al., 1995). More impor-
tantly, constitutive expression of human MxA in an otherwise
IFN-non-responsive animal confers full protection, demon-
strating the exquisite power of a single effector molecule of the
human IFN system in an otherwise susceptible host (Hefti et
al., 1999). A single autosomal dominant gene locus, designated
Flv/Wnv, is responsible for natural resistance of mice against
infection with West Nile virus (WNV) and other flaviviruses
(Brinton and Perelygin, 2003). The gene was recently
identified as Oas1b, a member of a large IFN-regulated gene
family encoding 2V-5V-oligoadenylate synthetases (2-5 OAS)
known to play an important role in antiviral defense (Mashimoet al., 2002; Perelygin et al., 2002). As in the case of the Mx
GTPase, OAS1b has antiviral activity and directly mediates
inhibition of WNV replication (Lucas et al., 2003; Perelygin et
al., 2002). In recent years, genetic analysis of innate immune
responses has exploded and has generated a wealth of new
information, as discussed below.
Pathways leading to IFN gene expression
Induction of type I (a/h) IFN gene expression is tightly
regulated. Recent findings suggest that cells make use of two
major but distinct cellular signal transduction pathways to
sense viruses and activate their type I IFN genes. Most cells of
the body including fibroblasts, hepatocytes and conventional
dendritic cells (cDCs) use the so-called classical pathway. They
have intracellular sensors that, upon infection, detect viral
components in the cytoplasm and activate the main interferon
regulatory transcription factors IRF-3 and NF-kB which in turn
transactivate IFN-h gene expression. Infected cells secrete
mainly IFN-h as an initial response to infection but switch to
IFN-a during the subsequent amplification phase of the IFN
response (Marie et al., 1998). In contrast, plasmacytoid
dendritic cells (pDCs) use Toll-like receptors (TLRs) expressed
on the cell surface or in endosomes to sense extracellular or
engulfed viral material. TLR signaling of pDCs primarily
involves the adaptor protein MyD88 and activates IRF-7 which
is constitutively expressed in pDCs and serves as a master
regulator of IFN-a/h gene expression (Honda et al., 2005b).
This cell type predominantly secretes high levels of IFN-a and
represents the so-called natural interferon producing cells of the
body (Colonna et al., 2002; Diebold et al., 2003). Both
pathways play important roles during infection and are
presently being fully explored.
Classical pathway
The classical pathway of type I IFN induction is best
understood for IFN-h gene expression in fibroblasts (Fig. 1).
In infected cells, a signaling chain is activated by double-
stranded RNA (dsRNA) molecules which are generated as
intermediates of viral transcription. Two intracellular RNA
helicases, RIG-I (Yoneyama et al., 2004) andMDA5 (Andrejeva
et al., 2004), act as sentinels for viral dsRNA detection. The two
related helicases are apparently non-redundant and seem to
function in parallel, having a degree of virus specificity
(Yoneyama et al., 2005). RIG-I and MDA5 are ubiquitously
expressed in most tissues and are inducible by IFNs which
allows autocrine and paracrine amplification of the sensing
system. A third member of the RIG-I helicase family, LGP2, is a
natural inhibitor which presumably masks the viral dsRNA from
recognition by RIG-I or MDA5 and serves as a negative
regulator of IFN gene expression (Rothenfusser et al., 2005;
Yoneyama et al., 2005). RIG-I and MDA5 both contain two N-
terminal caspase-recruiting domain (CARD)-like regions and a
C-terminal DExD/H box RNA helicase domain (Andrejeva et
al., 2004; Yoneyama et al., 2004). RNA-binding to the helicase
domain most likely induces a conformational change which
Fig. 1. Type I IFN induction, signaling and action. Left panel: dsRNA, a characteristic by-product of virus replication, leads to activation of the transcription factors
NF-nB, IRF-3 and AP-1 (not shown). The cooperative action of these factors is required for full activation of the IFN-h promoter. IRF-3 is phosphorylated by the
kinases IKK( and TBK-1 which in turn are activated by the RNA-sensing complex of RIG-I, MDA5 and IPS-1/MAVS. A second signaling pathway involves
endosomal TLR-3 and TRIF. Right panel: Newly synthesized IFN-h binds to the type I IFN receptor (IFNAR) and activates the expression of numerous ISGs via the
JAK/STAT pathway. IRF-7 amplifies the IFN response by inducing the expression of several IFN-h subtypes. SOCS and PIAS are negative regulators of the JAK-
STAT pathway. Mx, ISG20, OAS and PKR are examples of proteins with antiviral activity. For details see text.
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of downstream signaling partners (Kato et al., 2005; Yoneyama
et al., 2004). Indeed, one interaction partner has just been
identified independently by two groups. The novel protein is
required to mediate RIG-I and MDA5 signals to downstream
factors and is therefore called either IPS-1 for ‘‘interferon-h-
promoter stimulator 1’’ (Kawai et al., 2005) or MAVS for
‘‘mitochondrial antiviral signaling’’ molecule (Seth et al., 2005).
It is identical to an uncharacterized protein previously recog-
nized to be involved in NF-kB promoter activation (Matsuda et
al., 2003). IPS-1/MAVS has a CARD-like domain which binds
to RIG-I and MDA5 and a C-terminal region which interacts
with FADD and RIP1 which are both involved in NF-kB
signaling (Kawai et al., 2005). Surprisingly, IPS-1/MAVS
localizes to the outer mitochondrial membrane via a C-terminal
transmembrane domain. Membrane association and localization
to mitochondria is shown to be essential for function (Seth et al.,
2005). These findings are intriguing, as they link IFN production
and innate immune responses to mitochondrial activity. It is
conceivable that the membrane localization of IPS-1/MAVS is
advantageous as it may keep the interacting RNA-sensing
helicases close to the viral replication factories which often
develop in association with intracellullar membranes.
The downstream molecules interacting with IPS-1/MAVS
are not yet known. However, IPS-1/MAVS leads indirectly to
activation of the IRF-3 kinases (Fig. 1) (Kawai et al., 2005;
Seth et al., 2005). Two InB kinase (IKK)-related kinases, IKK(
and TANK-binding kinase-1 (TBK-1), are known to phos-
phorylate the transcription factor IRF-3 (Fitzgerald et al., 2003;
Sharma et al., 2003). IRF-3 is a member of the IFN regulatory
factor (IRF) family and plays a central role in the activation of
the IFN-h promoter (Lin et al., 1998; Schafer et al., 1998;
Wathelet et al., 1998; Weaver et al., 1998; Yoneyama et al.,
1998). Phosphorylated IRF-3 homodimerizes and moves intothe nucleus where it recruits the transcriptional coactivators
p300 and CREB-binding protein (CBP) to initiate IFN-h
mRNA synthesis (Hiscott et al., 1999; Suhara et al., 2002). In
addition, NF-nB and AP-1 are recruited in a dsRNA-dependent
way (Chu et al., 1999). Together these transcription factors
strongly up-regulate IFN-a/h gene expression. This initially
produced ‘‘first-wave’’ IFN triggers expression of a related
factor, IRF-7, which is normally not present in most cells or at
best in very low amounts (Sato et al., 2000). Genetic evidence
has recently shown that IRF-7 is the master regulator of IFN
gene expression and that IRF-3 most likely cooperates with
IRF-7 for full activity (Honda et al., 2005b). IRF-7 is activated
in the same way as IRF-3 (Iwamura et al., 2001; Smith et al.,
2001; tenOever et al., 2004) and is responsible for a positive-
feedback loop that initiates the synthesis of several IFN-a
subtypes as the ‘‘second-wave’’ IFNs (Marie et al., 1998; Sato
et al., 1998).
Some cells of the hematopoietic system such as cDCs
preferentially express TLR3 and can sense viral and other
dsRNA molecules in the endocytic compartment (Fig 1).
Ligand-induced triggering of TLR3 by dsRNA proceeds via
the adaptor molecule TRIF which bypasses IPS-1/MAVS and
directly activates the kinase TBK-1. This RIG-I-independent
process also leads to phosphorylation and nuclear translocation
of IRF-3 and IFN-h gene expression. The main difference is
that TLR-3-expressing cells do not need to get infected to
produce type I IFNs but can respond to viral RNA from
inactivated virus particles or dead cells provided they are taken
up in the endosomal compartment (Schulz et al., 2005).
TLR pathway in plasmacytoid dendritic cells
pDCs are specialized IFN producers and represent a major
source of IFN-a in humans (Colonna et al., 2002). They sense
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endosomes (Beutler, 2004; Bowie and Haga, 2005). Human
pDCs mostly express the TLR9 subfamily members TLR7,
TLR8 and TLR9 which recognize viral single-stranded (ss)
RNA (TLR7,8) or double-stranded CpG-rich DNA (TLR9),
respectively (Iwasaki and Medzhitov, 2004). Upon activation,
TLR7, 8 and 9 signal through their adaptor molecule MyD88
which forms a complex with TRAF6 and IRF-7 (Fig. 2). IRF-7
is phosphorylated by IRAK-1, an additional component of this
receptor-associated multiprotein complex, and transcriptionally
activates multiple IFN-a genes (Iwasaki and Medzhitov, 2004;
Uematsu et al., 2005). A key difference between pDCs and
other cell types is their capacity to constitutively express
considerable amounts of IRF-7 (Kerkmann et al., 2003;
Prakash et al., 2005). IRF-7 and also IRF-8 are further up-
regulated in response to IFN and together generate a positive
feed back loop for high IFN-a and IFN-h production (Asselin-
Paturel and Trinchieri, 2005; Tsujimura et al., 2003).
Another distinguishing feature is the recent finding that
ligand-bound TLR-9 and presumably also TLR-7/TLR8 remain
active in the endosomal compartment for a long time period,
whereas they are rapidly translocated to lysosomes and
degraded in other cell types (Honda et al., 2005a). It is perhaps
not surprising that some viruses which are known to causeFig. 2. TLR signaling pathway for IFN-a production in plasmacytoid dendritic
cells (pDCs). TLR7 and TLR8 respond to RNA viruses by recognizing ssRNA
in endosomes. In contrast, TLR9 responds to DNA viruses by recognizing
CpG-rich sequences. The receptors transmit their signals through an associated
multiprotein complex containing the adaptor protein MyD88 and the
transcription factor IRF-7. In contrast to most other cells, pDCs constitutively
express IRF-7 (Kerkmann et al., 2003; Prakash et al., 2005). Some pathogenic
viruses interfere with this pathway. See text for details.prolonged immunosuppression or immune imbalances should
target pDCs and inhibit IFN production induced by the TLR-
MyD88-IRF-7 pathway (Fig. 2), because type I IFNs play a
major role in shaping adaptive immune responses, in addition
to their function in innate immunity (Le Bon and Tough, 2002).
Recent examples are measles virus and respiratory syncytial
virus which block IFN production in pDCs by an as yet
unknown mechanism (Schlender et al., 2005).
IFN receptor signaling
The IFN receptor signaling pathway is now firmly
established and has appropriately been described in compre-
hensive reviews (Samuel, 2001; Stark et al., 1998). IFN-h
and the multiple IFN-a subspecies activate a common type I
IFN receptor (IFNAR) which sends a signal to the nucleus
through the so-called JAK-STAT pathway (Fig. 1). The
STAT proteins are latent cytoplasmic transcription factors
which become phosphorylated by the Janus kinases JAK-1
and TYK-2. Phosphorylated STAT-1 and STAT-2 recruit a
third factor, IRF-9 (or p48), to form a complex known as
IFN-stimulated gene factor 3 (ISGF-3) which translocates to
the nucleus and binds to the IFN-stimulated response
element (ISRE) in the promoter region of interferon-
stimulated genes (ISGs). Specialized proteins serve as
negative regulators and inhibitors of the JAK-STAT pathway.
The suppressor of cytokine signaling (SOCS) proteins
prevent STAT activation (Kubo et al., 2003) whereas protein
inhibitor of activated STAT (PIAS) family members function
as small ubiquitin-like modifier (SUMO) E3 ligases and
inhibit the transcriptional activity of STATs (Shuai and Liu,
2005). Interestingly, some of these inhibitors are exploited by
viruses to down-regulate IFN action (see below). Of great
interest in this context is a recent genetic analysis of
Drosophila C virus infection in its natural host Drosophila
melanogaster, because the findings demonstrate for the first
time a conserved function of the JAK-STAT signaling
pathway in insect antiviral immunity (Dostert et al., 2005).
It remains to be seen whether insect viruses possess evasion
strategies similar to those found in vertebrate viruses.
IFN-stimulated gene products with antiviral activity
Type I IFNs activate the expression of several hundred IFN-
stimulated genes (ISGs) (de Veer et al., 2001; Der et al., 1998)
some of which code for antiviral proteins (Fig. 1). To date,
three antiviral pathways have been firmly established. These
comprise the protein kinase R (PKR) (Williams, 1999), the 2-5
OAS/RNaseL system (Silverman, 1994) and the Mx proteins
(Haller and Kochs, 2002; Isaacs and Lindenmann, 1957). Mx
proteins belong to the superfamily of dynamin-like large
GTPases and have been discovered as mediators of genetic
resistance against orthomyxoviruses in mice. Their importance
for host survival following infection with certain RNA viruses
has been amply demonstrated (Arnheiter et al., 1996; Hefti et
al., 1999; Pavlovic et al., 1995) but their exact mode of action
is still unknown. The relevance of the OAS/RNaseL and PKR
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documented both in tissue culture and animal experiments. In
addition, their importance is highlighted by the fact that most
viruses have evolved specific mechanisms to counteract their
activities (see below). Mice lacking one of these components
show increased susceptibility to viral infections (Yang et al.,
1995; Zhou et al., 1997). Nevertheless, cells from so-called
triple knock-out mice lacking PKR, RNaseL and Mx still
exhibit a limited IFN-induced antiviral state, indicating that
additional antiviral pathways exist (Zhou et al., 1999).
Additional proteins with potentially important antiviral activ-
ities are ISG20 (Espert et al., 2003), promyelocytic leukemia
protein (PML) (Regad et al., 2001), guanylate-binding protein
1 (GBP-1) (Anderson et al., 1999), P56 (Guo et al., 2000; Hui
et al., 2003) and RNA-specific adenosine deaminase 1
(ADAR1) (Samuel, 2001). P56 binds a subunit of the
eukaryotic translation initiation factor eIF3 and thereby
suppresses viral as well as cellular RNA translation (Hui et
al., 2003; Wang et al., 2003). Importantly, both P56 and
ADAR1 are able to limit hepatitis C virus (HCV) replication to
some degree (Taylor et al., 2005; Wang et al., 2003).
Viral interference with cellular IFN responses
Most viruses need to multiply extensively to establish a
solid infection in the newly infected host and to provide an
outcrop of progeny virus for host-to-host transmission, or else
to secure viral persistence or latency. How can a virus reach
this goal in the presence of a powerful innate immune
response? The answer is that viruses have learned to cope
with the IFN system. Shortly after the discovery that heat-
inactivated influenza viruses would induce IFN (Isaacs and
Lindenmann, 1957), Jean Lindenmann reported that infection
of cells with a live influenza virus inhibited the subsequent
induction of IFN by an inactivated virus. He called this
puzzling phenomenon ‘‘inverse interference’’ (Lindenmann,
1960). It is now evident that most viruses have evolved means
to down-regulate IFN responses. In many cases they use non-
structural viral proteins for that purpose which are otherwise
non-essential for virus growth. This strategy can be exploited
in the laboratory to generate mutant viruses that lack the
relevant non-essential proteins. Such viruses still grow in IFN-
non-responsive cells or organisms but are highly attenuated in
IFN-competent hosts. Using such an approach, several
laboratories have already successfully produced novel vaccine
candidates lacking proteins with IFN-antagonistic activity
(Ferko et al., 2004; Talon et al., 2000b; Valarcher et al.,
2003). Current genetic analyses of many different viruses are
revealing an ever-growing number of IFN-antagonistic proteins
that target virtually all components of the IFN system. These
IFN antagonists are often multifunctional proteins that interact
with multiple viral or host cell components and are involved in
regulating many different functions in infected cells. For
example the NS1 of FLUAV is pleiotropic since it not only
binds to and sequesters dsRNA molecules to prevent induction
of IFNs (Garcia-Sastre, 2001; Garcia-Sastre et al., 1998; Talon
et al., 2000a; Wang et al., 2000) but also inhibits the 3V endprocessing of cellular pre-mRNAs, regulates the virus replica-
tion cycle and enhances translation initiation of viral mRNAs
(Krug et al., 2003). Comprehensive reviews have recently dealt
with these issues (Basler and Garcia-Sastre, 2002; Conzel-
mann, 2005; Gale and Foy, 2005; Hengel et al., 2005; Weber et
al., 2004). Here we will address some general points.
Fig. 3 illustrates the range of activities mediated by IFN
antagonists of various viruses. Only a few examples are listed
but they demonstrate several important points. First, viral
proteins or functions have been identified that cover the whole
spectrum of the IFN response in infected cells. Second, a single
viral protein may inhibit quite different components of the IFN
induction and signaling cascade. Third, a given virus may
display more than one IFN-antagonistic activity targeting
different pathways. Good examples are the V proteins of some
paramyxoviruses which bind to the dsRNA-sensing helicase
MDA5 and thereby block induction of IFN (Andrejeva et al.,
2004) but also provoke the ubiquitinylation and subsequent
degradation of STAT1 in a complex reaction (Didcock et al.,
1999; Palosaari et al., 2003; Precious et al., 2005; Ulane et al.,
2005). The NSs protein of Rift valley fever virus is a major
virulence factor (Bouloy et al., 2001) and blocks IFN
production by inhibiting the basic cellular transcription
machinery (Billecocq et al., 2004; Le May et al., 2004).
Surprisingly, it also activates the cellular suppressor of STAT
activation, SOCS-1, to impede IFN signaling (Miche`le Bouloy,
personal communication). Likewise, HSV-1 induces SOCS-3
to down-regulate STAT and JAK phosphorylation (Yokota et
al., 2004). Interestingly, the core protein of HCV also appears
to activate SOCS-3 (Bode et al., 2003), while the NS3/4A
protease of HCV inhibits RIG-I signaling and has also the
ability to disrupt TLR3 signaling by inducing cleavage of the
adaptor protein TRIF (Breiman et al., 2005; Foy et al., 2005; Li
et al., 2005). The NS3/4A protease is essential to cleave the
non-structural proteins from the HCV polyprotein synthesized
on intracellular membranes and may also lead to degradation of
the membrane-bound cellular IPS1/MAVS complexes.
In many negative-strand RNAviruses, the phosphoprotein P,
an essential component of the viral polymerase complex, is the
main IFN antagonist. For example, the P protein of Rabies
virus prevents IRF-3 phosphorylation by TBK-1 (Brzozka et
al., 2005). Likewise, the P protein (called VP35) of Ebola virus
(EBOV) interferes with IRF-3 activation (Basler et al., 2003).
The P protein of Borna disease virus (BDV) directly binds to
TBK-1 and reduces its activity (Unterstab et al., 2005). A
different strategy to block cellular IRF-3 is used by certain
herpesviruses. Human herpes virus 8 (HHV-8), the causative
agent of Kaposi sarcoma, displays viral IRF homologues,
termed vIRFs, which either mimic their cellular counterparts or
exert a dominant-negative effect (Burysek et al., 1999a, 1999b;
Li et al., 1998; Lubyova et al., 2004; Lubyova and Pitha, 2000;
Zimring et al., 1998). Finally, a far-reaching approach is used
by the large poxviruses. They can afford to express soluble
IFN-binding proteins which compete with the cellular receptor
for its IFN ligand (Alcami et al., 2000; Symons et al., 1995).
These ‘‘viroceptors’’ neutralize whatever IFN is secreted from
cells. They prevent the autocrine IFN amplification loop and –
Fig. 3. Viral inhibitors of the virus-induced IFN-a/h response loop: Viral gene products interfere with the type I IFN system at all levels. The following viral IFN
antagonists are shown in clockwise order: NS1 of FLUAV (Garcia-Sastre, 2001; Garcia-Sastre et al., 1998; Talon et al., 2000a; Wang et al., 2000), NS1 of FLUBV
(Dauber et al., 2004), E3LVV (Smith et al., 2001; Xiang et al., 2002), Vof paramyxoviruses (Andrejeva et al., 2004), NS3/4A of HCV (Breiman et al., 2005; Foy et
al., 2005), VP35 of EBOV (Basler et al., 2003), P of RV (Brzozka et al., 2005), P of BDV (Unterstab et al., in press), V, W of Nipah virus (Park et al., 2003; Shaw et
al., 2004), NS1/NS2 of RSV (Bossert et al., 2003; Spann et al., 2004; Valarcher et al., 2003), leader protein of TMEV (Delhaye et al., 2004; van Pesch et al., 2001),
ML of THOV (Hagmaier, 2003 #89;Jennings, 2004 #233;Pichlmair, 2004 #247), NPro of CSFV (La Rocca et al., 2005; Ruggli et al., 2003, 2005), vIRF and ORF45
of HHV-8 (Burysek et al., 1999a, 1999b; Li et al., 1998; Lubyova et al., 2004; Lubyova and Pitha, 2000; Zhu et al., 2002; Zimring et al., 1998), E6 of HPV16 (Ronco
et al., 1998), BZLF-1 of EBV (Hahn et al., 2005), M of VSV (Ahmed et al., 2003; Yuan et al., 1998), 3CPro of PV (Clark et al., 1993; Yalamanchili et al., 1996), NSs
of BUNV (Thomas et al., 2004; Weber et al., 2002), NSs of RVFV, (Billecocq et al., 2004; Bouloy et al., 2001; Le May et al., 2004), B18 and B8 of VV (Alcami et
al., 2000; Symons et al., 1995), JEV, WNV (Guo et al., 2005; Lin et al., 2004), E6 of HPV18 (Li et al., 1999), core protein of HCV (Bode et al., 2003; Keskinen et
al., 2002; Melen et al., 2004; Miller et al., 2004), HSV-1 (Yokota et al., 2004), NSs of RVFV (M. Bouloy, pers. communication), V, C, N of paramyxoviruses
(Andrejeva et al., 2002; Didcock et al., 1999; Garcin et al., 2002, 2004; Gotoh et al., 2003; Kato et al., 2001; Kubota et al., 2002; Palosaari et al., 2003; Parisien et al.,
2001; Rodriguez et al., 2002, 2003; Shaffer et al., 2003; Shaw et al., 2004; Takeuchi et al., 2001), NS4B of DHFV, WNV, and YFV (Jones et al., 2005; Munoz-
Jordan et al., 2003, 2005), E1A AdV (Leonard and Sen, 1996; Look et al., 1998), NS5A and E2 of HCV (Gale et al., 1998; Taylor et al., 1999), EBER of EBV (Elia
et al., 1996), VA of AdV (Kitajewski et al., 1986; Mathews and Shenk, 1991), K3L of VV (Davies et al., 1992). Not shown: Tat and TAR of HIV interfere with PKR
activation (Gunnery et al., 1990; Roy et al., 1990). g34.5 protein of HSV-1 reverts the translational block mediated by PKR (He et al., 1997). NS1 of influenza B
virus targets the IFN-induced ubiquitin-like modifier ISG15, the significance of which remains to be established (Krug et al., 2003). The M27 gene product of mouse
O. Haller et al. / Virology 344 (2006) 119–130124more importantly – the establishment of an antiviral state also
in the non-infected tissue surrounding the IFN-producing cells.
A fourth point worth discussing is the fact that the virus-
induced IFN response is generated in a cascade-like manner
(Fig. 3). Therefore, viral proteins blocking one component in
this circuit also affect distant signaling or effector molecules,
thereby amplifying their inhibitory effect. For example, JAK-
STAT inhibitors not only suppress the production of antiviral
proteins but also the expression of RIG-I, MDA5, IPS-1/
MAVS, IRF-3 and IRF-7 which are all IFN-inducible proteins.
As a consequence, production of the ‘‘second-wave’’ IFNs is
reduced. This enhanced down-regulation of IFN responses acts
against the IFN-activating effect of viral dsRNA molecules
which progressively accumulate in infected cells. The end-result is a balance between virus-promoting and virus-inhibit-
ing factors which may be optimal for each virus-host
relationship.
Interestingly, some lytic viruses causing acute infections
have adopted a radical strategy usually not found in non-lytic
viruses that persist in the body. Poliovirus, vesicular stomatitis
virus (VSV) and some bunyaviruses affect the basic cellular
transcription machinery and shut-off host gene transcription
(Ahmed et al., 2003; Billecocq et al., 2004; Clark et al., 1993;
Le May et al., 2004; Thomas et al., 2004; Weber et al., 2002;
Yalamanchili et al., 1996; Yuan et al., 1998). More specifically,
the non-structural protein NSs of RVFV has been demonstrated
to target the p44 component of the cellular transcription factor
IIH (TFIIH) which is an essential cofactor of the cellular RNA
O. Haller et al. / Virology 344 (2006) 119–130 125polymerase II (RNAP II) (Le May et al., 2004). Likewise, the
M protein of VSV inactivates TFIID, another RNAP II cofactor
(Yuan et al., 1998). Hence, some viral proteins are suppressors
of IFN gene expression through their general inhibitory effect
on host gene transcription (Ahmed et al., 2003; Billecocq et al.,
2004; Thomas et al., 2004). In addition, as already mentioned,
the NSs of RVFVactivates SOCS-1 and has a more specific but
indirect effect on the JAK-STAT pathway. To be effective, NSs
should be expressed at very early time points of infection. This
task would seem difficult to achieve, because NSs of RVFV is
transcribed in an ambisense coding strategy from the comple-
mentary anti-sense S segment which needs first to be
synthesized in infected cells. However, a recent report finds
that such anti-sense S segment RNAs are packaged into
infectious virus particles and can be transcribed into NSs
mRNA immediately after delivery to the cell cytoplasm. It is
suggested that the immediate availability of NSs protein may
provide a selective advantage in giving the virus a ‘‘head start’’
over the innate immune system (Ikegami et al., 2005).
Concluding remarks and outlook
The interplay between viruses and the IFN responses of
their hosts, as described here, is most likely the result of an
evolutionary race between the two genetic systems. The race
is ongoing, as emerging viruses compete for new hosts and
attempt trans-species transmission causing zoonotic infec-
tions, as illustrated by recent outbreaks of SARS-coronavirus,
Hendra and Nipah viruses, Ebola and Marburg viruses, or the
threat of transmission of H5N1 avian influenza viruses to
humans.
An emerging virus must overcome the IFN defenses of a
foreign host to be successful. There is ample evidence that viral
IFN antagonists exhibit a degree of species specificity and are
efficient in one species but not another (Bossert and Con-
zelmann, 2002; Chatziandreou et al., 2004; Parisien et al.,
2002; Young et al., 2001). However, adaptations are likely to
occur. This is best illustrated in arthropod-borne viruses. They
replicate in their blood-feeding arthropod hosts and are then
transmitted by bite to vertebrate hosts. To continue the
transmission cycle, virus replication in the vertebrate host
must proceed in the face of a vigorous IFN response. To
succeed, arboviruses have evolved specific viral proteins to
counteract the IFN system of the vertebrate host, as illustrated
in bunyavirus infections (Bouloy et al., 2001; Weber et al.,
2002). As invertebrates do not have equivalent IFN genes,
these viral IFN antagonists are most likely an adaptation to the
mammalian host, securing virus transmission. Another inter-
esting example is Thogoto virus (THOV), an influenza-like
virus transmitted by ticks to small rodents and, occasionally,
man. Its replication occurs in the cell nucleus and is sensitive to
inhibition by IFN-induced mouse Mx1 and human MxA
GTPases (Haller et al., 1995; Kochs and Haller, 1999). The
Mx block inhibits a very early step in the viral multiplication
cycle that affects primary transcription of the incoming
genome. Since the virus cannot transcribe and replicate its
genome in the presence of Mx, generation of Mx escapemutants is virtually impossible. Therefore, the prime strategy of
THOV is to suppress IFN production in the vertebrate host by
virtue of its ML protein and to avoid Mx expression in
potential target cells, as recently demonstrated in a mouse
model (Jennings et al., 2005; Pichlmair et al., 2004).
Future applications involve the genetic manipulation of viral
IFN antagonists for the development of novel candidate
vaccines. Viruses with targeted deletions in genes known to
code for IFN antagonists are promising candidates for live
virus vaccines. They grow well in tissue culture but are highly
attenuated in the host organism, due to a robust IFN and
immune response. This approach has been pioneered for
FLUAV (Ferko et al., 2004; Talon et al., 2000b) and for
bovine RSV (Valarcher et al., 2003), and may likewise apply to
other viruses.
Another fascinating development is the generation of
viruses that may be used as oncolytic agents. Mutations in
tumor cells often cripple the IFN system, favoring unhindered
proliferation and protection from apoptosis (Stojdl et al., 2000).
As a consequence, such cells become vulnerable to virus
infection. For example, PKR is switched off in tumor cells due
to transformation by p21ras (Mundschau and Faller, 1995).
Alternatively, defects in translational regulation render tumor
cells insensitive to PKR action (Balachandran and Barber,
2004). VSV or wild-type reoviruses are highly sensitive to
inhibition by PKR (Balachandran et al., 2000; Strong et al.,
1998) and preferentially infect cells which have an inactivated
PKR pathway (Balachandran and Barber, 2004; Coffey et al.,
1998). Therefore, selectivity for tumor cells can be increased
using genetically engineered viruses devoid of anti-IFN
proteins. Such viruses are unable to infect IFN-competent
body cells, but are still capable of efficiently replicating and
destroying the IFN-deficient tumor cells. A VSV variant with
mutations in the M gene inactivating its IFN-antagonistic
capacity was shown to specifically lyse tumors in immuno-
competent mice (Stojdl et al., 2003). Similarly, an HSV-1
lacking the gene for the anti-PKR protein g34.5 was
apathogenic even when administered intracerebrally (Hunter
et al., 1999), but it could destroy glioma cells (Mineta et al.,
1995).
Our present knowledge of the IFN system and viral
countermeasures is still limited. However, a better understand-
ing of the intimate interplay between viruses and innate
immune defenses will open new avenues for drug design,
vaccine development and anti-cancer strategies.
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